Dr. Poma has served as MTEM’s Chief Executive Officer and Chief Scientific Officer since the Company’s inception in 2009. From March 2005 until September 2008, Dr. Poma was Vice President of Business Development of Innovive Pharmaceuticals (acquired by Cytrx Corporation), a biotechnology company. From 2001 to 2005, he served as the Associate Vice President of Business Development at ImClone Systems, Inc.(now Eli Lilly and Company) a biotechnology company focused on antibody therapeutics. As the founder and in his role as Chief Scientific Officer at MTEM, he led the invention of technology underlying MTEM’s platform technology and what constitutes the whole of MTEM’s current lead and preclinical pipeline candidates. Dr. Poma received his Ph.D. in Microbiology and Immunology and B.A. in Biology and from the University of North Carolina at Chapel Hill and his M.B.A. from New York University.
Mr. Kim serves as MTEM’s President and Chief Operating Officer. He served as MTEM’s Chief Financial Officer from February 2010 to August 2017. Previously, Mr. Kim led corporate development and strategic planning initiatives at OSI Pharmaceuticals (acquired by Astellas) and ImClone Systems (acquired by Lilly). He served as an investment professional at Domain Associates and Safeguard Scientifics where he focused on venture and public investments in biotechnology. Mr. Kim holds an MBA from The Wharton School and a BA in Neuroscience from Wesleyan University.
Dr. Valacer joined Molecular Templates as Chief Medical Officer in 2014. Previously, Dr. Valacer served in a variety of integral clinical development and operational roles at Celgene, Boehringer Ingelheim, Genentech, and Roche. He received his M.D. from the University of Vermont College of Medicine followed by specialty and subspecialty training at Columbia Presbyterian Medical Center and the University of California at San Francisco. Dr. Valacer holds four board certifications including Clinical Immunology.
Dr. Higgins joined Molecular Templates in 2010 and serves as the Company’s EVP of Operations and Head of Manufacturing. Previously, Dr. Higgins held leadership roles in the translation research group at the National Cancer Institute developing therapeutic cancer vaccines. Dr. Higgins holds a PhD and MS from the University of Arkansas where he focused on discovering and developing bio-therapeutics for the treatment of enteric disease.
Dr. Willert joined Molecular Templates in 2011 and serves as the Company’s Executive Vice President of R&D. Previously, Dr. Willert conducted research efforts focused on immune regulation of viral gene expression and biochemical characterization of therapeutic drug targets for parasitic disease. Dr. Willert completed her post-doctoral research at the Department of Pathology and Immunology at Washington University School of Medicine. Dr. Willert holds a PhD in Biochemistry from the University of Texas Southwestern Medical Center in Dallas.
Dr. Liu joined Molecular Templates in 2012 and serves as the Company’s Executive Vice President of Manufacturing. Previously, Dr. Liu served in various scientific and leadership roles at XBiotech and the Cancer Research Institute of Scott & White Healthcare. Dr. Liu holds a PhD in Biochemistry from the University of Rochester in New York.